ESTRO 2021 Abstract Book

S1257

ESTRO 2021

left to live abroad. Toxicities and recurrences were collected. T oxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scoring system. Results Keloid incidence was slightly higher in men (57.9%) than women (42.1%). The earlobe was the most frequent location with 77.3% (17 of 22). Patient description and treatment details are summarized in Table 1.

With a median follow-up of 21.2 months a local control of 72.7% (16 of 22) was achieved. The overall recurrence rate was 22.7% (5 of 22).

One keloid recurred 12.2 months after completion of radiotherapy (Caucasian woman with a back lesion), one after 13.7 months (Caucasian man with a thorax keloid), 2 more recurrences happened after 21.2 months (Caucasian men with thorax and earlobe keloids) and finally one relapsed appeared at 62.6 months after radiotherapy (Black woman with earlobe keloid). All relapsed patients had already received previous treatments. Itching, skin tension and erythema grade 1 were the worse side effects in a minority of patients. There were no significant treatment related toxicities or secondary malignancies according to CTCAE v5 classification. Conclusion The follow up time is still short for some patients but treatments have resulted in an acceptable recurrence rate (22.7%) consistent with literature (10 – 23%). Recurrence rate of surgery alone can be as high as 80%. No toxicities or secondary cancers have been detected so far. Further analysis of recurrence rate and late toxicity with longer follow-up time should be done, but surgical excision followed by radiotherapy is an effective and safe option to be still considered for relapsed keloids with high risk of recurrence.